NPS Pharmaceuticals, Inc.

Bedminster, NJ 07921

Market Performance

NASDAQ: NPSP
52 Week High $46
52 Week Low $22

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $0.0
First Award Date 09/30/90
Most Recent Award Date 08/01/98

Key Personnel

Last Name Name Awards Contact
Nemeth Edward F Nemeth 3
Mueller Alan L Mueller 2
Bukoski Richard D Bukoski 1

6 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/98 - 07/31/00

DESCRIPTION (Adapted from applicant's abstract): The long term goal of the proposal is to develop anti-hypertension drugs based on the premise that a distinct form of the parathyroid Ca2+ receptor (CaR) exists in perivascular nerves and that stimulation of this receptor leads to elaboration of a vasodi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/04/95 - 01/31/96

DESCRIPTION: NMDA receptor antagonists may possess therapeutic utility for a variety of CNS pathologies, but NMDA receptor antagonists may elicit side effects including PCP-like psychotomimetic episodes. Early Araxin compounds discovered at NPS antagonize NMDA receptors at a unique site and by a novel mec...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 12/07/93 - 06/06/94

The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor has been implicated in a variety of neurological pathologies including ischemic brain damage (stroke), head trauma, spinal cord injury, epilepsy, neurodegenerative disorders such as Alzheimer's Disease, and hyperalgesic states. The development of NMDA antagonists as therapeutants, how...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/93 - 04/30/94

DESCRIPTION (Adapted from applicant's abstract):Recent studies demonstrate the presence of a calcium receptor protein on parathyroid cell that enables these cells to detect and respond to changes in the concentration of extracellular calcium. Drugs that act on this receptor to mimic the effects of extracellular calcium would offer a novel thera...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/92 - 04/30/93

DESCRIPTION (Adapted from applicant's abstract):Recent studies demonstrate the presence of a calcium receptor protein on parathyroid cell that enables these cells to detect and respond to changes in the concentration of extracellular calcium. Drugs that act on this receptor to mimic the effects of extracellular calcium would offer a novel thera...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/90 - 06/30/91

DESCRIPTION (Adapted from the Applicant's Abstract): Recent studies have provided evidence for the presence of a Ca2+ receptor on the surface of parathyroid cells which enables these cells to detect small changes in the concentration of extracellular Ca2+ and thereby alter parathyroid hormone secretion. This Ca2+ receptor is coupled to the mob...